Bristol-Myers Squibb Company (BMY)
NASDAQ • Healthcare
January 21, 2026 at 21:00 UTC
Name
CEO
Website
Industry
Year Founded
Employees
Bristol-Myers Squibb Company is a biopharmaceutical enterprise that discovers, develops, and commercializes medicines in oncology, immunology, cardiovascular disease, and other therapeutic areas. Research programs span biologics and small molecules guided by translational science, clinical development, and collaborations with academic groups and biotechnology partners. Manufacturing and quality systems support global supply for hospitals and pharmacies, while medical affairs and patient services help clinicians use therapies appropriately. The company engages regulators and health systems across North America, Europe, and key international markets, aligning access strategies with local standards of care. Within the healthcare ecosystem, Bristol-Myers Squibb contributes targeted treatments and pursues pipelines intended to address complex, chronic conditions.
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Bristol-Myers Squibb Company's Technical Indicators Summary
BMY is currently exhibiting a neutral technical profile, with momentum indicators like the RSI and CCI suggesting a cautious hold, while the Stochastic oscillator signals some short-term selling pressure. The ADX points to a moderately strong trend, supported by price remaining above key medium- and long-term moving averages, despite short-term averages indicating slight weakness. Volatility remains steady, as reflected by the average true range, and volume trends show some divergence with the on-balance volume suggesting selling interest. Overall, the technical landscape reflects a balance between bullish and bearish forces, resulting in a neutral stance. The current setup indicates consolidation rather than clear directional bias.
| Indicator | Value |
|---|---|
RSI (14) | 56.86 |
Stochastic %K (14, 3, 3) | 85.14 |
CCI (20) | 51.52 |
WPR (14) | -35.74 |
Momentum (10) | 1.80 |
MFI | 43.63 |
MACD Level (12, 26) | 1.31 |
Bollinger Bands | $52.57 - $57.24 |
ATR (14) | $1.22 (2.20%) |
ADX (14) | 35.92 |
OBV | 168,878,700 |
Simple Moving Averages | $48.31 - $55.65(5 indicators) |
Exponential Moving Averages | $50.34 - $55.64(5 indicators) |
Get premium market insights delivered directly to your inbox.
Trading kicked off on a mildly softer footing, with BMY gapping down -0.221% to 54.10 from 54.22. The open brings a very quiet tape for BMY, with participation down to 0.22× standard volume. BMY edges lower amid limited stock-specific headlines despite positive pipeline updates.
Price Change
from $54.22 close
+$0.09
Trading Volume
Below avg (13.5M)
2.9M
vs S&P 500 Today
Underperforming Market
-0.77%
52-Week Position
Mid-range
56.7%
Updated: January 21, 2026 at 15:35 UTC
Biopharma Leaders Map Growth at JPM 2026
January 13, 2026